| Company |
Product |
Therapeutic category |
Year of partnership |
| Novartis, India |
Vildagliptin |
Diabetes |
2008 |
| Roche |
Xenical |
Anti-Obesity |
2008 |
| Sebapharma, Germany |
Sebamed |
Cosmeceuticals |
2006 |
| Fujix Inc., Japan |
TripleACal |
Nutritional |
2004 |
| Kissei, Japan |
Kissei, Japan |
Diabetes |
2006 |
| Engelhard, Germany |
Prospan |
Respiratory |
2005 |
| Alfa Wassermann, Italy |
Fluxum |
Cardiology |
1994 |
| Cimab |
IORT3 |
Nephrology |
1994 |
| OM Pharma, Switzerland |
Broncho-Munal |
Respiratory |
2005 |
Fluxum and Triple A Cal are marketed in India for a number of years. We are the leaders in terms of units sales for Fluxum and have maintained this leadership position from the launch year. Triple A Cal is a specialized calcium and during the first 18 months we have reached No. 2 in terms of prescription generation. Prospan was launched in 2006 and we have sold more than 1.5 million bottles in 24 months. The response to Sebamed skin care range of products which was launched in 2007 is good.
To partner with us to establish a prime position for your brand in the Indian pharmaceutical market please mail bizdev@usv.co.in
|